CP, it looks like LabCorp (and which bought Covance) could use PS Targeting patents and related Biomarkers to shore up their future collaborations with BMS.
Hopefully CEO Roger Lias still has his contacts at Covance handy....because Covance would likely see the value in PS Targeting IP and Exosomes related Biomarkers....more than just residual values.
A federal judge has invalidated four patents on genetic tests to be used in cancer treatment belonging to a Laboratory Corporation of America Holdings unit, finding they claimed unpatentable laws of nature.
The ruling, handed down Wednesday by U.S. District Judge Allison Burroughs in Boston, is a victory for German diagnostics company Qiagen NV, which had challenged the patents. It follows an order from Burroughs in the same case last September invalidating a similar patent on the same grounds.
To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2bVuGx8